

# Mutant Alleles of *lptD* Increase the Permeability of *Pseudomonas aeruginosa* and Define Determinants of Intrinsic Resistance to Antibiotics

 Carl J. Balibar,<sup>a</sup> Marcin Grabowicz<sup>b</sup>

 Merck Research Laboratories, Kenilworth, New Jersey, USA<sup>a</sup>; Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA<sup>b</sup>

Gram-negative bacteria provide a particular challenge to antibacterial drug discovery due to their cell envelope structure. Compound entry is impeded by the lipopolysaccharide (LPS) of the outer membrane (OM), and those molecules that overcome this barrier are often expelled by multidrug efflux pumps. Understanding how efflux and permeability affect the ability of a compound to reach its target is paramount to translating *in vitro* biochemical potency to cellular bioactivity. Herein, a suite of *Pseudomonas aeruginosa* strains were constructed in either a wild-type or efflux-null background in which mutations were engineered in *LptD*, the final protein involved in LPS transport to the OM. These mutants were demonstrated to be defective in LPS transport, resulting in compromised barrier function. Using isogenic strain sets harboring these newly created alleles, we were able to define the contributions of permeability and efflux to the intrinsic resistance of *P. aeruginosa* to a variety of antibiotics. These strains will be useful in the design and optimization of future antibiotics against Gram-negative pathogens.

With emerging multidrug resistance and a limited number of treatment options, bacterial infections pose an ever growing threat to human health. Gram-negative bacteria are particularly recalcitrant to antimicrobial intervention due to their cell envelope structure. Possessing two membranes with different chemical properties (1) and containing an arsenal of efflux pumps (2), Gram-negative bacteria are capable of both excluding and expelling molecules, rendering them resistant to many drugs. Despite major Gram-negative pathogens being classified as urgent or serious threats by the CDC (3), no Gram-negative-active antibiotic with a new mechanism of action has been introduced in over 40 years. Of the 28 new antibiotics approved since 2000, only 18 are indicated for treatment of Gram-negative bacteria (4), and all of those are derived from the four legacy classes  $\beta$ -lactams, tetracyclines, macrolides, and fluoroquinolones, which were first introduced in 1942 (5), 1948 (6), 1952 (7), and 1967 (8), respectively. Novel derivatives of old antibiotics often have limited spectra of coverage and can only do so much to overcome existing mechanisms of resistance; therefore, introduction of novel classes of antibiotics is critical.

There is no shortage of potential targets in the antibacterial space given that the essential gene set for several Gram-negative pathogens has been defined (9–12). However, despite genetically demonstrating target essentiality, cognate inhibitors with exquisite *in vitro* activity often have no measurable cellular activity (13, 14). The reasons for this can be attributed to a lack of penetration of compounds into bacteria, efflux of molecules out of bacteria, insufficient inhibition of the target, metabolism within the cells, or a combination of the aforementioned factors. Understanding the reason for failure to translate enzymatic 50% inhibitory concentrations (IC<sub>50</sub>s) into cellular MICs is paramount to an antibacterial research and development program and guides medicinal chemistry efforts. As a model organism for Gram-negative pathogens, many genetic tools have been developed for *Escherichia coli* in order to assess the contributions of efflux and permeability to intrinsic resistance. Strains exist with efflux pumps knocked out either individually or in combination, and the relative contribu-

tion of each system to the susceptibility to major classes of antimicrobials has been defined (15). For the most part, *tolC* is the major contributor to efflux in *E. coli*, and knockout of this gene is often used to assess whether novel compounds lack cellular activity due to efflux (16–24). Similarly, mutations in several genes—including *lpxC* (25–27), *lptD* (28, 29), and *lptE* (30, 31)—leading to increased permeability of *E. coli* have been described, and strains harboring such lesions are often used to assess the effect of increased cellular penetration on the bioactivity of molecules (32–37). These three genes in particular are often targeted because of their essential role in biosynthesis and biogenesis of lipopolysaccharide (LPS), which comprises the outer leaflet of the outer membrane (OM) in Gram-negative organisms and greatly contributes to reduced permeability. *LpxC* is a zinc-dependent deacetylase that forms UDP-3-O-(hydroxytetradecanoyl)glucosamine in the committed step of lipid A biosynthesis (38), and *LptD* and *LptE* constitute a  $\beta$ -barrel and plug, respectively, responsible for the final step of LPS transport to the OM (39–41).

Although *E. coli* serves as a powerful model for studying Gram-negative bacteria, findings are not always recapitulated in other more serious pathogens, in particular *Pseudomonas aeruginosa*. *P. aeruginosa* is a common nosocomial pathogen that often takes advantage of immunocompromised hosts to cause infections associated with high rates of mortality (42, 43). It is perhaps best

Received 20 July 2015 Returned for modification 26 August 2015

Accepted 15 November 2015

Accepted manuscript posted online 23 November 2015

 Citation Balibar CJ, Grabowicz M. 2016. Mutant alleles of *lptD* increase the permeability of *Pseudomonas aeruginosa* and define determinants of intrinsic resistance to antibiotics. *Antimicrob Agents Chemother* 60:845–854. doi:10.1128/AAC.01747-15.

Address correspondence to Carl J. Balibar, carl.balibar@merck.com.

 Supplemental material for this article may be found at <http://dx.doi.org/10.1128/AAC.01747-15>.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

known as the major cause of declining lung function in cystic fibrosis (CF) patients (44). Among Gram-negative bacteria, *P. aeruginosa* is particularly resistant to antimicrobial intervention because it has a large and diverse set of multidrug efflux pumps (45, 46) and an especially impermeable OM (47, 48), and it can metabolize antimicrobial compounds (43). Although the permeability of the lipid bilayer domain of *P. aeruginosa*, as assessed by measuring the influx of hydrophobic steroid probes, is comparable to those of other Gram-negative bacteria such as *Salmonella enterica* serovar Typhimurium and *E. coli* (48, 49), a limitation to the influx of molecules comes from OprF, the major porin of *P. aeruginosa*. Responsible for slow nonspecific diffusion of solutes into the bacterium, it has been shown that OprF folds into two conformations, with less than 5% of the porin present in the open-channel conformer, severely limiting penetration of molecules into the bacterium (50). It is for this multitude of reasons that often agents which are active on most other Gram-negative bacteria are less effective on *Pseudomonas aeruginosa* (13, 51–53), and finding compounds that inhibit this organism can be difficult. Again, it is imperative to understand the roles efflux and permeability play in the intrinsic resistance of this organism when developing the next generation of antibiotics. As with *E. coli*, collections of efflux pump-null strains of *P. aeruginosa* have been created which help to define the substrate specificities of the various pumps (43, 54, 55). However, *P. aeruginosa* efflux pumps are more numerous and redundant than those of *E. coli*, and often strains with multiple pump knockouts are necessary to assess the full effect of efflux on compound activity (13, 56–58). In contrast, techniques for assessing the effects of permeability in *P. aeruginosa* are less refined. Rather than single defined mutations, as utilized in *E. coli*, membrane permeabilization is often induced with chemical treatment using reagents such as polymyxin B nonapeptide (PMBN), compound 48/80, and EDTA (59–66). The latter two reagents can be harsh, inconsistent, and have incomplete effects, have intrinsic bioactivity, and can induce pleiotropic effects on the bacteria. PMBN at low concentrations is considered to be more specific, as it interacts with LPS to increase permeability, but the effects are dose dependent, and PMBN does have intrinsic growth-inhibitory activity at higher concentrations (67). A more elegant and defined system would be desired for assessment of the role of permeability in compound susceptibility in *P. aeruginosa*.

Herein we describe the creation of a suite of *Pseudomonas aeruginosa* mutants in which the final protein involved in transporting LPS for OM biogenesis was compromised in either a wild-type (WT) background or an efflux-deficient mutant. These strains were utilized to assess the activity of multiple classes of antibiotics and to determine the activity-limiting component in *P. aeruginosa*.

## MATERIALS AND METHODS

**General reagents.** All DNA was purified using either the QIAprep spin miniprep kit, DNeasy blood and tissue kit, QIAquick gel extraction kit, or QIAquick PCR purification kit (Qiagen, Valencia, CA). Phusion high-fidelity polymerase and restriction enzymes PstI and BamHI were from New England BioLabs (Ipswich, MA). In-Fusion HD enzyme mix was from Clontech (Mountain View, CA). Electroporation was performed on a Gene Pulser II electroporator with Gene Pulser cuvettes (Bio-Rad, Hercules, CA). DNA sequencing was performed by Genewiz, Inc. (South Plainfield, NJ). LB, LB agar (LBA), super optimal broth (SOB) medium, cation-adjusted Mueller-Hinton broth (CAMHB), cation-adjusted Mueller-Hinton agar (CAMHA), tryptone, yeast extract, and the BBL Prompt

system were from Becton-Dickinson/Difco (Franklin Lakes, NJ). *E. coli* mating strain RHO3 (68), pEX18Ap plasmid (69), and associated protocols were provided by H. P. Schweizer (Colorado State University). All primers, diaminopimelate (DAP), sodium nitrate (NaNO<sub>3</sub>), sucrose, EDTA, PMBN, ampicillin, clindamycin, linezolid, colistin, rifampin, tetracycline, ciprofloxacin, novobiocin, fusidic acid, and vancomycin were from Sigma-Aldrich (St. Louis, MO). Gentamicin was from Fisher Scientific (Waltham, MA). Carbenicillin was from Research Products International (Mount Prospect, IL). Azithromycin was from USP (Rockville, MD). Imipenem was from Merck (Kenilworth, NJ).

***Pseudomonas* strain construction.** Mutant alleles *lptE6* (30), *lpxC101* (25), *lptD4213* (28, 70), *lptD208* (28, 70), and *lptDΔ529–538* (71) were constructed in the suicide vector pEX18Ap (69). Mutations were incorporated into internal primers, which were used to PCR amplify the corresponding gene, in full, in two fragments composed of regions flanking the desired mutation. Upstream and downstream regions were amplified using primer pairs P1/P2 and P3/P4 for *lptE6*, P5/P6 and P7/P8 for *lpxC101*, P9/P10 and P11/P12 for *lptD4213*, P9/P13 and P14/P12 for *lptD208*, and P9/P15 and P16/P12 for *lptDΔ529–538* (Table 1). In a second-round PCR, splicing by overlap extension was used to combine up- and downstream products with external primers P1/P4, P5/P8, and P9/P12 for *lptE6*, *lpxC101*, and the *lptD* alleles, respectively. These complete alleles were then cloned into a BamHI/PstI-digested pEX18Ap vector using In-Fusion HD enzyme. After sequencing to confirm the correct alleles had been made, plasmids were mobilized from *E. coli* RHO3 (68) into a wild-type *P. aeruginosa* PAO1 strain termed MB5919 (56) and an efflux-deficient *P. aeruginosa* PAO1  $\Delta(mexAB-oprM)::FRT \Delta(mexCD-oprI)::FRT \Delta(mexXY)::FRT \Delta(mexJKL)::FRT \Delta(mexHI-opmD)::FRT \Delta(opmH)::FRT$  mutant termed MB5890 (57) (see Table S1 in the supplemental material). Briefly, overnight cultures of the RHO3 donor grown in SOB medium containing 400  $\mu$ g/ml DAP and 100  $\mu$ g/ml ampicillin were diluted 1/100 into 3 ml fresh culture medium and grown to mid-log phase. Overnight cultures of the *P. aeruginosa* recipient grown in SOB medium were diluted 1:1 in 500  $\mu$ l 20 mM NaNO<sub>3</sub> and incubated at 42°C for 3 h. Both cultures were subsequently washed with 1 ml SOB medium and resuspended in 200  $\mu$ l SOB medium. Ten microliters of recipient *P. aeruginosa* cells and 60  $\mu$ l donor RHO3 *E. coli* cells were mixed, plated as a dime-sized plane of growth on CAMHA plus 400  $\mu$ g/ml DAP, and incubated overnight at 37°C. The next day, a loop was dragged twice through the heaviest part of the plane of growth, resuspended in 200  $\mu$ l CAMHB, and diluted 1/100, and then 70  $\mu$ l was plated on CAMHA containing either 150  $\mu$ g/ml carbenicillin (for MB5919) or 40  $\mu$ g/ml carbenicillin (for MB5890). Exconjugates were confirmed for carbenicillin resistance and sucrose sensitivity. No exconjugates were ever obtained for the *lptE6* allele.

To resolve cointegrants to double-crossover mutants, single colonies were restreaked onto LB with no salt (LBNS: 10 g/liter tryptone, 5 g/liter yeast extract) with 10% (wt/vol) sucrose to select for loss of the *sacB*-containing vector backbone. The resulting colonies were patched onto LBNS, LBNS containing carbenicillin (40  $\mu$ g/ml for MB5890 and 150  $\mu$ g/ml for MB5919), and LBNS containing 6  $\mu$ g/ml rifampin in order to screen for growth, loss of the antibiotic resistance cassette-containing vector backbone, and increased permeability, respectively. Resolved mutants demonstrating the desired Carb<sup>r</sup> Rif<sup>r</sup> phenotype were obtained for the *lptD4213* and *lptD208* mutants, and sequencing across *lptD* confirmed mutant allele exchange. For the alleles *lpxC101* and *lptDΔ529–538*, hundreds of colonies were screened, and resolved mutants were found to be Carb<sup>r</sup> but never Rif<sup>r</sup>. Over 40 resolved clones for each of these constructs were sent for sequencing across *lpxC* or *lptD*, respectively, but only wild-type sequence was ever observed.

Unmarked *pagP* (PA1343) knockouts were constructed in MB5919 and MB5890 using the pEX18Ap suicide plasmid. Flanking regions encompassing 600 bp upstream (through the first 50 nucleotides [nt] of *pagP*) and 600 bp downstream (including the last 50 nt of *pagP*) were amplified using primer pairs P17/P18 and P19/P20, respectively, and then

TABLE 1 Primers used for strain construction

Gene and primer name	Sequence <sup>a</sup>
<i>lptE</i>	
P1	ccaagcttgcagcctgcagGCCAGCACCACAAGTTCAACAC
P2	TGCACCTGTACGCGCATCAGGACCAGGTCGTTGGC
P3	TGGTCCTGATGCGCGTACAGGTGCAGAAGGTCTAC
P4	cggtaccgggatccGGCGAATCCACTGCGGCAACTG
<i>lpxC</i>	
P5	ccaagcttgcagcctgcagCGCGGGTCCGGACCTGTCCCTG
P6	TTTTCCCCGAATACAGACCCGACGCCAGTAGCCCG
P7	GCGTCGGTCTGTATTGCGGGGAAAAGGTTTACCTG
P8	cggtaccgggatccAGGCATCGACCCAGTTGTCTGC
<i>lptD</i>	
P9	ccaagcttgcagcctgcagGCCGGTTCGAACAGCTCGTGC
P10	TTGGTTGACGTACGTACCTCGGCCAGCCAGCGCGA
P11	TGGCTGGCCGAGGTCACGTACGTCAACCAACGGGGC
P12	cggtaccgggatccTCTTGCCCATGTCCGAGGCAAG
P13	GCGATAGGTCAGAGTGATCCGCGTGTAGTCGACCTC
P14	GACTACACGCGGATCACTCTGACCTATCGCGGGGAC
P15	CTCGGCCACAGAGAGAAGACCGGCAGGCTGTCTTG
P16	AGCCTGCCGTTCTTCTCTGTGGCGGAGAACCGC
<i>pagP</i>	
P17	ccaagcttgcagcctgcagAAGGGAATCGAAGCGTCACGGTGAC
P18	CGAATTGCCGAGCAGCACCAGCCAGGAGGTCGCGCGAGCAC
P19	GTGCTCGCCGACCTGCCTGGCTGGTGTCTCGGCAATTCG
P20	cggtaccgggatccGACACCGAGAGTTGGCGGTCTTGCTGAAG

<sup>a</sup> Underlining denotes a restriction site. The transition from lowercase to capital letters denotes the boundary between the vector and gene sequence.

subsequently combined through splicing by overlap extension using the external primers P17/P20. The final PCR product was cloned into pEX18Ap, transformed into *E. coli* RHO3, mobilized into *P. aeruginosa*, and resolved to the double-crossover knockout as described above. MB5919Δ*pagP* and MB5890Δ*pagP* were confirmed by sequencing across the *pagP* gene.

**MIC testing.** MICs were determined by the broth microdilution method in CAMHB as recommended by the Clinical and Laboratory Standards Institute (72) in conjunction with the BBL Prompt system. The MIC was scored as the lowest concentration of compounds required to inhibit visible growth after 18 to 22 h of incubation while stationary at 37°C.

**Lipid A palmitoylation assay.** Overnight cultures were subcultured 1:100 into 5 ml of fresh CAMHB containing 5 μCi/ml <sup>32</sup>PO<sub>4</sub>. Cultures were grown with aeration at 37°C until they reached an optical density at 600 nm (OD<sub>600</sub>) of ~1; where indicated, cultures were then treated with 25 mM EDTA for 10 min. Lipid A was isolated as previously described (73). Briefly, cells were pelleted in a clinical centrifuge and washed with phosphate-buffered saline (PBS). Cells were resuspended in a single-phase Bligh-Dyer mixture of chloroform-methanol-water (1:2:0.8 [vol/vol]). Cells were lysed in the mixture for 10 min. The insoluble fraction was collected, resuspended in 12.5 mM sodium acetate (pH 4.5) and 1% SDS, and then incubated at 100°C for 30 min. Lipid A was then isolated from a two-phase Bligh-Dyer extraction and dried under a stream of nitrogen. Samples were resuspended in methanol-chloroform (1:4) mixture, and equivalent amounts were spotted onto a silica thin-layer chromatography (TLC) plate (Macherey-Nagel, Bethlehem, PA). TLC was developed using chloroform, pyridine, 88% formic acid, and water (50:50:16:5 [vol/vol]). Plates were dried and exposed to a phosphor storage screen overnight. Samples were visualized by imaging the screen using a Typhoon scanner (GE, Pittsburgh, PA).

## RESULTS

**Construction of *P. aeruginosa* mutants.** In order to bridge the gap between *in vitro* potency and cellular efficacy in *P. aeruginosa*, matched isogenic mutants of *P. aeruginosa* were constructed containing mutations putatively leading to permeability defects in a wild-type and multiple-efflux-pump-knockout background. Previous studies have described mutations leading to hyperpermeable (antibiotic hypersusceptibility) phenotypes in *E. coli*, including mutations in *lptD*, *lptE*, and *lpxC*. Sequence alignment of these genes' proteins from *E. coli* and *P. aeruginosa* indicated a fair amount of homology, so five mutant alleles—*lptE6* (30), *lpxC101* (25), *lptD4213* (28, 70), *lptD208* (28, 70), and *lptDΔ529–538* (71)—were engineered into *P. aeruginosa* in order to assess whether they would confer similar permeability defects (Fig. 1). Only two of these alleles, *lptD4213* and *lptD208*, were found to be viable. These results held true whether mutants were constructed in the wild-type MB5919 or efflux-deficient MB5890 strain background.

**Assessing antibiotic susceptibility of *P. aeruginosa* *lptD* mutants.** To assess the effect of the *lptD4213* and *lptD208* mutations on *P. aeruginosa*, strains were tested for susceptibility to a panel of antibiotics. A diverse array of scaffolds comprising a wide array of physicochemical properties were chosen, with compounds spanning a molecular size of 337 to 1,449 g/mol, a calculated value of overall lipophilicity (clogP) of −2.9 to 6.4, a relative polar surface area of 19.5 to 48.3%, 3 to 36 free rotatable bonds, and 8 to 54 hydrogen bond donors and acceptors (74). Antibiotics included classes with activity on Gram-negative bacteria (β-lactam, polymyxin, tetracycline, fluoroquinolone, and aminoglycoside) and

*lptE6* (PIS117-119R)

\*\*\*

*Ec* LptE (82) IAKDTASVFRNGQTAEYQMIMTVNATVLIP-GRDIYPISAKVFRSFFDNP  
*Pa* LptE (78) NQQRIVSYTGSARGAEFELTNTINYEIVGANDLVLMNSQVQVKVYVHDE

*lpxC101/envA* (H19Y)

\*

*Ec* LpxC (1) MIKQRTLKRIVQATGVGLHTGKKVTLTLRPAPANTGVIYR  
*Pa* LpxC (1) MIKQRTLKNIIRATGVGLHSGEKVYLTLKPAPVDTGIVFC

*imp4213* ( $\Delta$ 330–352)*imp208* ( $\Delta$ 335–359)

\*\*\*\*\*  
 \*\*\*\*\*

*Ec* LptD (321) MDQVWRFNVDYTKVSDPSYFNDFDNKYGSSTDGYATQKFSVGYAVQNFNA  
*Pa* LptD (416) LDSRWLAEDYTRISDPYFQDLDTDLGVGSTTYVNQRGTLTYRGDTFTG

*lptD* $\Delta$ 529–538

\*\*\*\*\*

*Ec* LptD (506) QTLEPRAQYLYVPYRDQSDIYNYDSSLLQSDYSGLFRDRITYGGLDRIASA  
*Pa* LptD (628) QTLEPRAMYLYVPYKDQDSLVPVDTSEPSFSYDSLWRENRFYTKDRIGDA

**FIG 1** Alignment of LptE, LpxC, and LptD protein sequences from *E. coli* (*Ec*) and *P. aeruginosa* (*Pa*). Permeability-conferring alleles are listed with the resulting amino acid changes indicated in parentheses, and mutations are illustrated above the sequence with asterisks. Identical residues are highlighted in gray.

those which typically are inactive on Gram-negative bacteria (lincosamide, oxazolidinone, glycopeptide, rifamycin, aminocoumarin, fusidic acid, and macrolide). As can be seen in Table 2, both *lptD4213* and *lptD208* had a dramatic effect on the susceptibility to several antibiotics. MICs decreased by at least 32-fold for rifampin, ciprofloxacin, tetracycline, novobiocin, and azithromycin in the wild-type MB5919 background, and similar decreases could be observed for fusidic acid and carbenicillin when tested in the MB5890 efflux-null background. Although fold changes in MIC were difficult to assess for vancomycin because activity was not observed at the highest concentration tested (256  $\mu$ g/ml) in either MB5919 or MB5890, both *lptD4213* and *lptD208* led to

increased susceptibility of the strains and measurable MICs in the range tested. Notably, neither *lptD4213* nor *lptD208* had significant effects on the susceptibility of *P. aeruginosa* to gentamicin, clindamycin, or linezolid, with efflux contributing the majority of intrinsic resistance for the latter two. This might be expected given that these three antibiotics are rather small and polar and would not necessarily be subject to exclusion by the LPS barrier of the OM. Taken together, these results indicate that both *lptD4213* and *lptD208* successfully impart a permeability defect to *P. aeruginosa* and facilitate penetration of large hydrophobic antibiotics which normally are incapable of traversing the OM of this organism.

In *P. aeruginosa*, entry of imipenem is facilitated by the OM

**TABLE 2** *In vitro* MICs of various antibiotics against wild-type and permeable *P. aeruginosa* strains

Antibiotic	MB5919				MB5890			
	MIC ( $\mu$ g/ml)				MIC ( $\mu$ g/ml)			
	WT	Mutant		Fold change	WT	Mutant		Fold change
	<i>lptD4213</i>	<i>lptD208</i>			<i>lptD4213</i>	<i>lptD208</i>		
Clindamycin	>256	>256	256	NC <sup>a</sup>	8	4	4	2
Linezolid	>256	>256	>256	NC	4	4	4	1
Imipenem	4	1	0.5	4–8	2	0.5	1	2–4
Vancomycin	>256	64	32	>4–8	>256	128	128	>2
Colistin	1	0.125	0.25	4–8	0.5	0.125	0.125	4
Rifampin	32	0.5	0.5	64	32	1	1	32
Tetracycline	16	2	0.5	8–32	0.25	0.125	0.125	2
Ciprofloxacin	2	0.0625	0.032	32–64	0.004	0.004	0.004	1
Novobiocin	>256	8	8	>32	64	1	2	32–64
Carbenicillin	16	2	4	4–8	4	0.125	0.125	32
Fusidic acid	>256	>256	128	>2	64	2	2	32
Azithromycin	256	2	2	128	8	0.125	0.125	64
Gentamicin	0.5	0.125	0.25	2–4	0.5	0.25	0.5	1–2

<sup>a</sup> NC, not calculated due to lack of activity at the highest concentration tested.

**TABLE 3** *In vitro* MICs of  $\beta$ -lactam antibiotics against *oprD* mutant *P. aeruginosa* strains with and without permeability-inducing alleles

Antibiotic	MB6477				MB6476			
	MIC ( $\mu$ g/ml)				MIC ( $\mu$ g/ml)			
	WT	Mutant		Fold change	WT	Mutant		Fold change
		<i>lptD4213</i>	<i>lptD208</i>			<i>lptD4213</i>	<i>lptD208</i>	
Imipenem	16	0.5	0.5	32	8	1	1	8
Carbenicillin	32	1	2	16–32	4	0.125	0.125	32

porin OprD. Altered expression levels (75), changes in amino acid sequence (76), and complete knockout (77) of this protein are frequently associated with carbapenem resistance. It was of interest to know whether the permeability defects imparted by the *lptD4213* and *lptD208* alleles could compensate for loss of OprD-mediated entry of imipenem. To this end,  $\Delta$ *oprD* mutants of MB5890 and MB5919, termed MB6476 and MB6477, respectively, were constructed and subsequently engineered to introduce the two *lptD* mutations. When imipenem and a control  $\beta$ -lactam that is not specifically transported by OprD, the carbapenem carbenicillin, were tested for activity in these strains, OprD loss had the greatest effect on imipenem, resulting in a 4-fold increase in the MIC whether in an efflux-competent or -deficient background (Table 3). Introduction of either *lptD4213* or *lptD208* greatly increased susceptibility to imipenem, with resulting MICs of 0.5 to 1  $\mu$ g/ml, irrespective of efflux capacity, which is equivalent to the MIC range for imipenem in the parental *oprD*<sup>+</sup> MB5890 and MB5919 strains harboring the same permeability defects. Therefore, *lptD4213* and *lptD208* allow for greater penetration of imipenem than even that afforded by a known substrate-accepting porin.

Furthermore, we sought to compare the permeability defect caused by the *lptD4213* and *lptD208* alleles to the potentiation achieved with the chemical permeabilizer PMBN. As previously reported, PMBN had little intrinsic activity on the wild-type strain MB5919 (67) but had a MIC of 25.6  $\mu$ g/ml for the efflux-deficient MB5890 strain. Maximal antibiotic potentiation was essentially achieved with 4  $\mu$ g/ml PMBN, and this was sufficiently below the MIC for MB5890 to make comparisons. For the most part, MICs in the presence of PMBN (Tables 4 and 5) were within 2-fold of those achieved when strains harbored either the *lptD4213* or

*lptD208* allele (Table 2). The most significant differences were that PMBN potentiated rifampin 16-fold more than either mutant *lptD* allele in both MB5919 and MB5890, fusidic acid 16-fold more in the MB5919 background, and ciprofloxacin up to 8-fold less in the MB5919 background. This may indicate that PMBN is somewhat better at potentiating certain hydrophobic compounds, but the mutant *lptD* alleles may be better at potentiating certain hydrophilic compounds.

**Assessment of OM integrity in *P. aeruginosa* *lptD* mutants.** We sought to determine if these *lptD* mutations caused LPS transport defects in the *P. aeruginosa* OM. In Gram-negative cells, the OM inner leaflet consists exclusively of phospholipids (PLs), while the outer leaflet is comprised primarily of LPS (78, 79). Mutations that cause defects in LPS transport allow PLs to mislocalize to the outer leaflet and accumulate (41, 80). These mislocalized PLs become available as the substrates of the OM enzyme PagP, which removes the PL *sn*-1 palmitoyl group and transfers it to the lipid A component of LPS (81, 82). The PagP palmitoylation reaction increases the acylation of LPS, and the presence of such LPS species is used diagnostically to identify compromised OM integrity (41, 80). For example, treatment of cells with EDTA causes loss of LPS from the cell surface, which allows PLs to mislocalize to the OM outer leaflet, triggering PagP palmitoylation of LPS (73).

*P. aeruginosa* has long been known to palmitoylate its LPS, but only recently has a *pagP* homolog (PA1343) been identified in PAO1 and shown to function as a palmitoyltransferase (83). We constructed a  $\Delta$ *pagP*-null mutant and isolated the <sup>32</sup>P-radiolabeled lipid A component of LPS from this strain as well as from the *lptD4213* and *lptD208* mutants and the wild-type parent. Lipid A species were separated using thin-layer chromatography as described in Materials and Methods. Two major lipid A species were

**TABLE 4** *In vitro* MICs of various antibiotics against wild-type *P. aeruginosa* strain MB5919 in the presence of various concentrations of PMBN

Antibiotic	MIC ( $\mu$ g/ml) at PMBN concn ( $\mu$ g/ml) shown							
	0	0.26	0.66	1.6	4.1	10.2	25.6	64.0
Clindamycin	>256	>256	>256	>256	256	128	128	64
Linezolid	>256	>256	>256	>256	>256	>256	>256	>256
Imipenem	4	4	4	1	0.5	0.5	0.25	0.063
Vancomycin	>256	>256	>256	64	32	32	16	16
Colistin	1	1	0.5	0.5	0.5	0.25	0.25	0.25
Rifampin	32	32	32	1	0.031	0.031	0.031	0.031
Tetracycline	16	16	16	2	1	1	1	1
Ciprofloxacin	2	2	2	0.5	0.25	0.25	0.25	0.125
Novobiocin	>256	>256	>256	256	4	4	4	1
Carbenicillin	16	16	16	2	2	2	2	1
Fusidic acid	>256	>256	>256	>256	8	8	4	1
Azithromycin	256	256	256	4	2	2	2	1
Gentamicin	0.5	0.5	0.5	0.25	0.25	0.25	0.25	0.25

TABLE 5 *In vitro* MICs of various antibiotics against efflux-deficient *P. aeruginosa* strain MB5890 in the presence of various concentrations of PMBN

Antibiotic	MIC ( $\mu\text{g/ml}$ ) at PMBN concn ( $\mu\text{g/ml}$ ) shown							
	0	0.26	0.66	1.6	4.1	10.2	25.6	64
Clindamycin	8	8	8	2	2	2	NG <sup>a</sup>	NG
Linezolid	4	4	4	2	2	2	NG	NG
Imipenem	2	2	1	0.5	0.5	0.5	NG	NG
Vancomycin	>256	>256	>256	128	128	64	NG	NG
Colistin	0.5	0.5	0.25	0.25	0.25	0.125	NG	NG
Rifampin	32	32	16	0.031	0.031	0.016	NG	NG
Tetracycline	0.25	0.25	0.25	0.125	0.125	0.125	NG	NG
Ciprofloxacin	0.004	0.004	0.004	0.002	0.002	0.002	NG	NG
Novobiocin	64	64	64	16	1	1	NG	NG
Carbenicillin	4	4	4	0.5	0.25	0.25	NG	NG
Fusidic acid	64	64	64	8	8	1	NG	NG
Azithromycin	8	8	8	0.5	0.5	0.25	NG	NG
Gentamicin	0.5	0.5	0.5	0.25	0.25	0.25	NG	NG

<sup>a</sup>NG, no growth.

produced by wild-type and  $\Delta\text{pagP}$  strains (Fig. 2). We then isolated lipid A from these strains following treatment with 25 mM EDTA. Two novel lipid A species were produced by the wild type in response to EDTA treatment but were not produced by EDTA-treated  $\Delta\text{pagP}$  cells. Clearly, the appearance of these novel lipid A species is PagP dependent, and these therefore represent palmitoylated lipid A species. The same PagP-modified lipid A species are highly abundant in *lptD4213*- and *lptD208*-harboring *P. aeruginosa* strains without the need for EDTA treatment (Fig. 2), confirming that the organization of the OM lipid bilayer is severely disrupted in these mutant strains.

## DISCUSSION

Despite the need for novel Gram-negative antibiotics, new classes with alternative mechanisms of action have not been forthcoming.

Failure can often be attributed to an inability to achieve cellular activity with target-based *in vitro* inhibitors, perhaps caused by initial hits occupying the wrong physicochemical property space (13, 14, 74). When there is success in attaining cellular bioactivity, close attention must be paid to overcoming intrinsic resistance mechanisms such as efflux and permeability. Such efforts have shown promise in recent years with the development of hydroxamate LpxC inhibitors (84–86), novel bacterial type II topoisomerase inhibitors (NBTIs) (87, 88), tricyclic GyrB/ParE (TriBE) inhibitors (89), and pyrrolocytosine ribosome inhibitors (90). Although these classes of compounds have not yet reached clinical utility, they demonstrate progress and inspire confidence that novel Gram-negative antibiotics can be discovered.

One of the tools missing for assessment of determinants of compound activity in the major pathogen *P. aeruginosa* is a defined genetic means of measuring the contribution of permeability to intrinsic resistance. An antibiotic-hypersusceptible mutant, termed Z61, has been used to assess the effect of increased permeability on compound activity in *P. aeruginosa* (91–93); however this mutant was derived through multiple rounds of mutagenesis and contains hundreds of single nucleotide polymorphisms (SNPs) (94). Since numerous suppressors could be isolated with a spectrum of partial to full phenotypic reversion (91) and independent mutations could be identified leading to supersusceptibility to subsets of antimicrobial agents (95)—including *oprM*, *ampC*, *lptE*, and *amgRS* (94)—the Z61 strain is undoubtedly genetically complex, and hypersusceptibility cannot be solely attributed to defects in permeability. Additionally, the *E. coli* porin OmpF has been introduced into *P. aeruginosa*, resulting in strains significantly more susceptible to penem antibiotics (96). Given that porin expression was driven off a plasmid, results could vary due to expression level, and increased permeability is likely limited to smaller hydrophilic molecules.

Herein, we have created defined single mutations which lead to a general permeabilization of *P. aeruginosa*. This approach allows construction of isogenic strain sets that can separate the effects of compound influx from efflux and guide compound design to address the activity-limiting factor. The two mutations described herein, *lptD4213* and *lptD208*, are overlapping deletions in LptD, a  $\beta$ -barrel protein responsible for the final step of LPS transport and




FIG 2 Mutations in *P. aeruginosa* *lptD* cause cells to produce LPS palmitoylated by PagP. LPS was extracted from stationary-phase cultures of MB5890 as well as  $\Delta\text{pagP}$ , *lptD208*, or *lptD4213* derivative strains that were grown in CAMHB and radiolabeled with  $^{32}\text{P}$ . Where indicated, cultures were treated with 25 mM EDTA for 15 min before sample collection. Samples were developed by TLC and visualized using a phosphor screen. The two major lipid A species produced in wild-type cells are denoted as “wt.” The two major PagP-dependent lipid A species are marked with asterisks.

assembly in the OM (40, 41, 70, 71). Based on recent crystal structures (97, 98), both mutations lead to the deletion of the alpha-helical loop L4 situated on the extracellular surface of the protein, as well as a portion of either  $\beta 7$  or  $\beta 8$ , respectively. Deletion of this loop may impair LptD function by reducing a few hydrogen bond interactions with the LptE plug and increasing extracellular access to the lumen of the  $\beta$ -barrel. Interestingly, one of the attempted mutations that was found to be nonviable, *lptD* $\Delta$ 529–538, is also in LptD. However, this mutation leads to deletion of a large loop, L8, between  $\beta 14$  and  $\beta 15$ , which extends much further into the lumen of the LptD  $\beta$ -barrel and makes extensive interactions with LptE. As was similarly suggested by the *lptE6* mutation, which was found to be dominant negative, the interactions between LptD and LptE may be particularly critical in *P. aeruginosa*, and significant disruption may be lethal.

In both the wild-type MB5919 and efflux-deficient MB5890 backgrounds, the *lptD4213* and *lptD208* alleles were demonstrated to impart significant permeability defects, as assessed by increased susceptibility to a range of antibiotics. The power of these defined genetic lesions and the use of isogenic strain sets are exemplified by the ability to define the activity-limiting component for the antibiotics tested. We determined that efflux was the major contributor to intrinsic resistance for clindamycin and linezolid, with the OM barrier providing minimal protection. Conversely, imipenem, vancomycin, colistin, and rifampin were found to be poor substrates for efflux, and their activity was mostly limited by poor entry into *P. aeruginosa*. For ciprofloxacin and tetracycline, efflux was the main factor limiting activity as *lptD4213* or *lptD208* mutations did not sensitize MB5890. However, in the wild-type MB5919 background, introduction of the *lptD4213* and *lptD208* alleles did reduce the MICs between 16- and 32-fold, indicating that increased penetration of ciprofloxacin and tetracycline into *P. aeruginosa* could overwhelm the efflux pumps and increase their bioactivity. For novobiocin, carbenicillin, fusidic acid, and azithromycin, both efflux and the OM barrier function contribute to intrinsic resistance, as mutations in either lead to additive improvements in potency. Finally, for gentamicin, neither efflux nor permeability appears to be a limiting factor for activity, as mutations in either did not significantly increase the susceptibility of *P. aeruginosa*.

LPS palmitoylation by PagP in strains harboring *lptD4213* and *lptD208* demonstrated that these alleles cause defects that disrupt the lipid asymmetry of the OM bilayer. Similar defects resulting in PagP-modified LPS can be observed upon depletion of the LptD and LptE proteins in *E. coli* (41, 80). The LPS perturbation observed in these mutants genetically phenocopies the results observed by chemical perturbation using reagents such as EDTA. As such, these strains will be extremely useful in antibacterial discovery to track activity of weakly bioactive compounds and to optimize hits from both phenotypic and biochemical screens.

In addition to being useful tools for delineating the factors affecting susceptibility to particular compounds, these permeability mutants will be useful in understanding basic biology related to outer membrane protein (OMP) assembly and LPS transport. Indeed, in *E. coli*, chemical conditionality was used in conjunction with the *lptD4213* allele to screen for suppressors of vancomycin (and related analogs) susceptibility, leading to identification of several components of the  $\beta$ -barrel assembly machinery, including *bamA* (99) and *bamB* (100, 101). Furthermore, it was the initial *E. coli lptD4213* strain that was used to determine that LptD

was involved in OM biogenesis (70) and ultimately responsible for LPS transport (39–41). To date, there have been limited studies exploring *P. aeruginosa*  $\beta$ -barrel assembly and the interplay with LptD function and LPS transport. As this study implies, the inability to engineer certain *lptE* and *lptD* alleles in *P. aeruginosa* that are viable in *E. coli* suggests that differences in the function of the LPS transport and  $\beta$ -barrel assembly machinery exist between organisms. This is further supported by the discovery of an extremely potent *P. aeruginosa*-specific LptD inhibitor that shows no activity on other Gram-negative organisms (102, 103). Clearly these systems are of importance and represent valuable targets for the development of novel antibiotics.

## FUNDING INFORMATION

Merck & Co., Inc. provided funding to Carl J. Balibar and Marcin Grabowicz.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

## REFERENCES

- Silhavy TJ, Kahne D, Walker S. 2010. The bacterial cell envelope. Cold Spring Harb Perspect Biol 2:a000414. <http://dx.doi.org/10.1101/cshperspect.a000414>.
- Schweizer HP. 2012. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 7:633–642. <http://dx.doi.org/10.1517/17460441.2012.688949>.
- CDC. 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA. <http://www.cdc.gov/drugresistance/threat-report-2013/>.
- Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 66:571–591. <http://dx.doi.org/10.1038/ja.2013.86>.
- Henderson JW. 1997. The yellow brick road to penicillin: a story of serendipity. Mayo Clin Proc 72:683–687.
- Nelson ML, Levy SB. 2011. The history of the tetracyclines. Ann N Y Acad Sci 1241:17–32. <http://dx.doi.org/10.1111/j.1749-6632.2011.06354.x>.
- Brittain DC. 1987. Erythromycin. Med Clin North Am 71:1147–1154.
- Emmerson AM, Jones AM. 2003. The quinolones: decades of development and use. J Antimicrob Chemother 51(Suppl 1):S13–S20.
- Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2:2006.0008.
- Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski DV, Brittnacher MJ, Manoil C. 2015. Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii. J Bacteriol 197:2027–2035. <http://dx.doi.org/10.1128/JB.00131-15>.
- Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci U S A 103:2833–2838. <http://dx.doi.org/10.1073/pnas.0511100103>.
- Wang N, Ozer EA, Mandel MJ, Hauser AR. 2014. Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung. mBio 5:e01163-14. <http://dx.doi.org/10.1128/mBio.01163-14>.
- Brown DG, May-Dracka TL, Gagnon MM, Tommasi R. 2014. Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J Med Chem 57:10144–10161. <http://dx.doi.org/10.1021/jm501552x>.
- Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40. <http://dx.doi.org/10.1038/nrd2201>.
- Sulavik MC, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J, DiDomenico B, Shaw KJ, Miller GH, Hare R, Shimer G. 2001. Antibiotic susceptibility profiles of Escherichia coli strains lacking mul-

- tidrug efflux pump genes. *Antimicrob Agents Chemother* 45:1126–1136. <http://dx.doi.org/10.1128/AAC.45.4.1126-1136.2001>.
16. Nayar AS, Dougherty TJ, Ferguson KE, Granger BA, McWilliams L, Stacey C, Leach LJ, Narita S, Tokuda H, Miller AA, Brown DG, McLeod SM. 2015. Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay. *J Bacteriol* 197:1726–1734. <http://dx.doi.org/10.1128/JB.02552-14>.
  17. McLeod SM, Fleming PR, MacCormack K, McLaughlin RE, Whiteaker JD, Narita S, Mori M, Tokuda H, Miller AA. 2015. Small-molecule inhibitors of Gram-negative lipoprotein trafficking discovered by phenotypic screening. *J Bacteriol* 197:1075–1082. <http://dx.doi.org/10.1128/JB.02352-14>.
  18. Humnabadkar V, Prabhakar KR, Narayan A, Sharma S, Gupta S, Manjrekar P, Chinnappattu M, Ramachandran V, Hameed SP, Ravishankar S, Chatterji M. 2014. UDP-N-acetylmuramic acid L-alanine ligase (MurC) inhibition in a tolC mutant *Escherichia coli* strain leads to cell death. *Antimicrob Agents Chemother* 58:6165–6171. <http://dx.doi.org/10.1128/AAC.02890-14>.
  19. Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS. 2011. Novel bacterial NAD<sup>+</sup>-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. *Antimicrob Agents Chemother* 55:1088–1096. <http://dx.doi.org/10.1128/AAC.01181-10>.
  20. Buurman ET, Andrews B, Gao N, Hu J, Keating TA, Lahiri S, Otterbein LR, Patten AD, Stokes SS, Shapiro AB. 2011. In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in *Haemophilus influenzae*. *J Biol Chem* 286:40734–40742. <http://dx.doi.org/10.1074/jbc.M111.274068>.
  21. Buurman ET, Foulk MA, Gao N, Laganas VA, McKinney DC, Moustakas DT, Rose JA, Shapiro AB, Fleming PR. 2012. Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in *Haemophilus influenzae*. *J Bacteriol* 194:5504–5512. <http://dx.doi.org/10.1128/JB.01103-12>.
  22. Uria-Nickelsen M, Neckermann G, Sriram S, Andrews B, Manchester JI, Carcanague D, Stokes S, Hull KG. 2013. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines. *Int J Antimicrob Agents* 41:363–371. <http://dx.doi.org/10.1016/j.ijantimicag.2012.12.001>.
  23. de Jonge BL, Walkup GK, Lahiri SD, Huynh H, Neckermann G, Utley L, Nash TJ, Brock J, Martin MS, Kutschke A, Johnstone M, Laganas V, Hajec L, Gu RF, Ni HH, Chen BD, Hutchings K, Holt E, McKinney D, Gao N, Livchak S, Thresher J. 2013. Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. *Antimicrob Agents Chemother* 57:6005–6015. <http://dx.doi.org/10.1128/AAC.01661-13>.
  24. Basarab GS, Brassil P, Doig P, Galullo V, Haimes HB, Kern G, Kutschke A, McNulty J, Schuck VJ, Stone G, Gowravaram M. 2014. Novel DNA gyrase inhibiting spiroimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization. *J Med Chem* 57:9078–9095. <http://dx.doi.org/10.1021/jm501174m>.
  25. Beall B, Lutkenhaus J. 1987. Sequence analysis, transcriptional organization, and insertional mutagenesis of the *envA* gene of *Escherichia coli*. *J Bacteriol* 169:5408–5415.
  26. Normark S. 1970. Genetics of a chain-forming mutant of *Escherichia coli*. Transduction and dominance of the *envA* gene mediating increased penetration to some antibacterial agents. *Genet Res* 16:63–78.
  27. Normark S, Boman HG, Matsson E. 1969. Mutant of *Escherichia coli* with anomalous cell division and ability to decrease episomally and chromosomally mediated resistance to ampicillin and several other antibiotics. *J Bacteriol* 97:1334–1342.
  28. Sampson BA, Misra R, Benson SA. 1989. Identification and characterization of a new gene of *Escherichia coli* K-12 involved in outer membrane permeability. *Genetics* 122:491–501.
  29. Charlson ES, Werner JN, Misra R. 2006. Differential effects of yfgL mutation on *Escherichia coli* outer membrane proteins and lipopolysaccharide. *J Bacteriol* 188:7186–7194. <http://dx.doi.org/10.1128/JB.00571-06>.
  30. Chimalakonda G, Ruiz N, Chng SS, Garner RA, Kahne D, Silhavy TJ. 2011. Lipoprotein LptE is required for the assembly of LptD by the beta-barrel assembly machine in the outer membrane of *Escherichia coli*. *Proc Natl Acad Sci U S A* 108:2492–2497. <http://dx.doi.org/10.1073/pnas.1019089108>.
  31. Grabowicz M, Yeh J, Silhavy TJ. 2013. Dominant negative *lptE* mutation that supports a role for LptE as a plug in the LptD barrel. *J Bacteriol* 195:1327–1334. <http://dx.doi.org/10.1128/JB.02142-12>.
  32. Caetano T, Krawczyk JM, Mosker E, Sussmuth RD, Mendo S. 2011. Lichenicidin biosynthesis in *Escherichia coli*: licFGEHI immunity genes are not essential for lantibiotic production or self-protection. *Appl Environ Microbiol* 77:5023–5026. <http://dx.doi.org/10.1128/AEM.00270-11>.
  33. Cunningham ML, Kwan BP, Nelson KJ, Bensen DC, Shaw KJ. 2013. Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay. *J Biomol Screen* 18:1018–1026. <http://dx.doi.org/10.1177/1087057113487208>.
  34. Fischer E, Wolf H, Hantke K, Parmeggiani A. 1977. Elongation factor-Tu resistant to kirromycin in an *Escherichia coli* mutant altered in both *tuf* genes. *Proc Natl Acad Sci U S A* 74:4341–4345. <http://dx.doi.org/10.1073/pnas.74.10.4341>.
  35. Good L, Sandberg R, Larsson O, Nielsen PE, Wahlestedt C. 2000. Antisense PNA effects in *Escherichia coli* are limited by the outer-membrane LPS layer. *Microbiology* 146:2665–2670. <http://dx.doi.org/10.1099/00221287-146-10-2665>.
  36. Langsdorf EF, Malikzay A, Lamarr WA, Daubaras D, Kravec C, Zhang R, Hart R, Monsma F, Black T, Ozbal CC, Miesel L, Lunn CA. 2010. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay. *J Biomol Screen* 15:52–61. <http://dx.doi.org/10.1177/1087057109355319>.
  37. Scudamore RA, Beveridge TJ, Goldner M. 1979. Outer-membrane penetration barriers as components of intrinsic resistance to beta-lactam and other antibiotics in *Escherichia coli* K-12. *Antimicrob Agents Chemother* 15:182–189. <http://dx.doi.org/10.1128/AAC.15.2.182>.
  38. Young K, Silver LL, Bramhill D, Cameron P, Eveland SS, Raetz CR, Hyland SA, Anderson MS. 1995. The *envA* permeability/cell division gene of *Escherichia coli* encodes the second enzyme of lipid A biosynthesis. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase. *J Biol Chem* 270:30384–30391.
  39. Bos MP, Tefsen B, Geurtsen J, Tommassen J. 2004. Identification of an outer membrane protein required for the transport of lipopolysaccharide to the bacterial cell surface. *Proc Natl Acad Sci U S A* 101:9417–9422. <http://dx.doi.org/10.1073/pnas.0402340101>.
  40. Chng SS, Ruiz N, Chimalakonda G, Silhavy TJ, Kahne D. 2010. Characterization of the two-protein complex in *Escherichia coli* responsible for lipopolysaccharide assembly at the outer membrane. *Proc Natl Acad Sci U S A* 107:5363–5368. <http://dx.doi.org/10.1073/pnas.0912872107>.
  41. Wu T, McCandlish AC, Gronenberg LS, Chng SS, Silhavy TJ, Kahne D. 2006. Identification of a protein complex that assembles lipopolysaccharide in the outer membrane of *Escherichia coli*. *Proc Natl Acad Sci U S A* 103:11754–11759. <http://dx.doi.org/10.1073/pnas.0604744103>.
  42. Morita Y, Tomida J, Kawamura Y. 2014. Responses of *Pseudomonas aeruginosa* to antimicrobials. *Front Microbiol* 4:422. <http://dx.doi.org/10.3389/fmicb.2013.00422>.
  43. Poole K. 2011. *Pseudomonas aeruginosa*: resistance to the max. *Front Microbiol* 2:65. <http://dx.doi.org/10.3389/fmicb.2011.00065>.
  44. Govan JR, Deretic V. 1996. Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and Burkholderia cepacia. *Microbiol Rev* 60:539–574.
  45. Poole K. 2004. Efflux-mediated multidrug resistance in Gram-negative bacteria. *Clin Microbiol Infect* 10:12–26.
  46. Poole K. 2005. Efflux-mediated antimicrobial resistance. *J Antimicrob Chemother* 56:20–51. <http://dx.doi.org/10.1093/jac/dki171>.
  47. Hancock RE, Woodruff WA. 1988. Roles of porin and beta-lactamase in beta-lactam resistance of *Pseudomonas aeruginosa*. *Rev Infect Dis* 10:770–775. <http://dx.doi.org/10.1093/clinids/10.4.770>.
  48. Plesiat P, Nikaido H. 1992. Outer membranes of Gram-negative bacteria are permeable to steroid probes. *Mol Microbiol* 6:1323–1333. <http://dx.doi.org/10.1111/j.1365-2958.1992.tb00853.x>.
  49. Plesiat P, Aires JR, Godard C, Kohler T. 1997. Use of steroids to monitor alterations in the outer membrane of *Pseudomonas aeruginosa*. *J Bacteriol* 179:7004–7010.
  50. Sugawara E, Nagano K, Nikaido H. 2012. Alternative folding pathways of the major porin OprF of *Pseudomonas aeruginosa*. *FEBS J* 279:910–918. <http://dx.doi.org/10.1111/j.1742-4658.2012.08481.x>.

51. Ulu-Kilic A, Alp E, Altun D, Cevahir F, Kalin G, Demiraslan H. 2015. Increasing frequency of *Pseudomonas aeruginosa* infections during tige-cycline use. *J Infect Dev Ctries* 9:309–312. <http://dx.doi.org/10.3855/jidc.4700>.
52. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. 1999. In vitro and in vivo antibacterial activities of a novel glycolycycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). *Antimicrob Agents Chemother* 43:738–744.
53. Reck F, Ehmman DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenjnih-Snyder N. 2014. Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against *Pseudomonas aeruginosa*. *Bioorg Med Chem* 22:5392–5409. <http://dx.doi.org/10.1016/j.bmc.2014.07.040>.
54. Schweizer HP. 2003. Efflux as a mechanism of resistance to antimicrobials in *Pseudomonas aeruginosa* and related bacteria: unanswered questions. *Genet Mol Res* 2:48–62.
55. Li XZ, Plesiat P, Nikaido H. 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev* 28: 337–418. <http://dx.doi.org/10.1128/CMR.00117-14>.
56. Robertson GT, Doyle TB, Du Q, Duncan L, Mdluli KE, Lynch AS. 2007. A novel indole compound that inhibits *Pseudomonas aeruginosa* growth by targeting MreB is a substrate for MexAB-OprM. *J Bacteriol* 189:6870–6881. <http://dx.doi.org/10.1128/JB.00805-07>.
57. Singh SB, Dayananth P, Balibar CJ, Garlisi CG, Lu J, Kishii R, Takei M, Fukuda Y, Ha S, Young K. 2015. Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent. *Antimicrob Agents Chemother* 59:3474–3481. <http://dx.doi.org/10.1128/AAC.00382-15>.
58. Caughlan RE, Sriram S, Daigle DM, Woods AL, Buco J, Peterson RL, Dzink-Fox J, Walker S, Dean CR. 2009. Fmt bypass in *Pseudomonas aeruginosa* causes induction of MexXY efflux pump expression. *Antimicrob Agents Chemother* 53:5015–5021. <http://dx.doi.org/10.1128/AAC.00253-09>.
59. Hancock RE, Wong PG. 1984. Compounds which increase the permeability of the *Pseudomonas aeruginosa* outer membrane. *Antimicrob Agents Chemother* 26:48–52. <http://dx.doi.org/10.1128/AAC.26.1.48>.
60. Vaara M. 1992. Agents that increase the permeability of the outer membrane. *Microbiol Rev* 56:395–411.
61. Champlin FR, Hart ME. 1990. Cell envelope impermeability to daptomycin in *Pseudomonas aeruginosa* and *Pasteurella multocida*. *Curr Microbiol* 21:367–372. <http://dx.doi.org/10.1007/BF02199439>.
62. Morris CM, George A, Wilson WW, Champlin FR. 1995. Effect of polymyxin-B nonapeptide on daptomycin permeability and cell-surface properties in *Pseudomonas aeruginosa*, *Escherichia coli*, and *Pasteurella multocida*. *J Antibiot (Tokyo)* 48:67–72. <http://dx.doi.org/10.7164/antibiotics.48.67>.
63. Mamelli L, Petit S, Chevalier J, Giglione C, Lieutaud A, Meinel T, Artaud I, Pages JM. 2009. New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors. *PLoS One* 4:e6443. <http://dx.doi.org/10.1371/journal.pone.0006443>.
64. Champlin FR, Ellison ML, Bullard JW, Conrad RS. 2005. Effect of outer membrane permeabilisation on intrinsic resistance to low triclosan levels in *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 26:159–164. <http://dx.doi.org/10.1016/j.ijantimicag.2005.04.020>.
65. Personne Y, Curtis MA, Wareham DW, Waite RD. 2014. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. *J Antimicrob Chemother* 69:3236–3243. <http://dx.doi.org/10.1093/jac/dku309>.
66. Barbosa MD, Lin S, Markwalder JA, Mills JA, DeVito JA, Teleha CA, Garlapati V, Liu C, Thompson A, Trainor GL, Kurilla MG, Pompliano DL. 2002. Regulated expression of the *Escherichia coli* *lepB* gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro. *Antimicrob Agents Chemother* 46:3549–3554. <http://dx.doi.org/10.1128/AAC.46.11.3549-3554.2002>.
67. Viljanen P, Vaara M. 1984. Susceptibility of Gram-negative bacteria to polymyxin B nonapeptide. *Antimicrob Agents Chemother* 25:701–705. <http://dx.doi.org/10.1128/AAC.25.6.701>.
68. Lopez CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dual-technology system for markerless allele replacement in *Burkholderia pseudomallei*. *Appl Environ Microbiol* 75:6496–6503. <http://dx.doi.org/10.1128/AEM.01669-09>.
69. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 212:77–86. [http://dx.doi.org/10.1016/S0378-1119\(98\)00130-9](http://dx.doi.org/10.1016/S0378-1119(98)00130-9).
70. Braun M, Silhavy TJ. 2002. Imp/OstA is required for cell envelope biogenesis in *Escherichia coli*. *Mol Microbiol* 45:1289–1302. <http://dx.doi.org/10.1046/j.1365-2958.2002.03091.x>.
71. Freinkman E, Chng SS, Kahne D. 2011. The complex that inserts lipopolysaccharide into the bacterial outer membrane forms a two-protein plug-and-barrel. *Proc Natl Acad Sci U S A* 108:2486–2491. <http://dx.doi.org/10.1073/pnas.1015617108>.
72. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed, vol 32. Clinical and Laboratory Standards Institute, Wayne, PA.
73. Jia WY, El Zoebiy A, Petruzzello TN, Jayabalasingham B, Seyedirashti S, Bishop RE. 2004. Lipid trafficking controls endotoxin acylation in outer membranes of *Escherichia coli*. *J Biol Chem* 279:44966–44975. <http://dx.doi.org/10.1074/jbc.M404963200>.
74. O'Shea R, Moser HE. 2008. Physicochemical properties of antibacterial compounds: implications for drug discovery. *J Med Chem* 51:2871–2878. <http://dx.doi.org/10.1021/jm700967e>.
75. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, *ampC*, and *oprD* expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 50:1633–1641. <http://dx.doi.org/10.1128/AAC.50.5.1633-1641.2006>.
76. Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, Zizi M. 2002. Analysis of the *Pseudomonas aeruginosa* *oprD* gene from clinical and environmental isolates. *Environ Microbiol* 4:872–882. <http://dx.doi.org/10.1046/j.1462-2920.2002.00281.x>.
77. Quinn JP, Dudek EJ, Divincenzo CA, Lucks DA, Lerner SA. 1986. Emergence of resistance to imipenem during therapy for *Pseudomonas aeruginosa* infections. *J Infect Dis* 154:289–294. <http://dx.doi.org/10.1093/infdis/154.2.289>.
78. Malinverni JC, Silhavy TJ. 2009. An ABC transport system that maintains lipid asymmetry in the Gram-negative outer membrane. *Proc Natl Acad Sci U S A* 106:8009–8014. <http://dx.doi.org/10.1073/pnas.0903229106>.
79. Nikaido H. 2003. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol Mol Biol Rev* 67:593–656. <http://dx.doi.org/10.1128/MMBR.67.4.593-656.2003>.
80. Ruiz N, Gronenberg LS, Kahne D, Silhavy TJ. 2008. Identification of two inner-membrane proteins required for the transport of lipopolysaccharide to the outer membrane of *Escherichia coli*. *Proc Natl Acad Sci U S A* 105:5537–5542. <http://dx.doi.org/10.1073/pnas.0801196105>.
81. Bishop RE, Gibbons HS, Guina T, Trent MS, Miller SI, Raetz CR. 2000. Transfer of palmitate from phospholipids to lipid A in outer membranes of Gram-negative bacteria. *EMBO J* 19:5071–5080. <http://dx.doi.org/10.1093/emboj/19.19.5071>.
82. Bishop RE. 2008. Structural biology of membrane-intrinsic beta-barrel enzymes: sentinels of the bacterial outer membrane. *Biochim Biophys Acta* 1778:1881–1896. <http://dx.doi.org/10.1016/j.bbame.2007.07.021>.
83. Thaipisuttikul I, Hittle LE, Chandra R, Zangari D, Dixon CL, Garrett TA, Rasko DA, Dasgupta N, Moskowitz SM, Malmstrom L, Goodlett DR, Miller SI, Bishop RE, Ernst RK. 2014. A divergent *Pseudomonas aeruginosa* palmitoyltransferase essential for cystic fibrosis-specific lipid A. *Mol Microbiol* 91:158–174. <http://dx.doi.org/10.1111/mmi.12451>.
84. Tomaras AP, McPherson CJ, Kuhn M, Carifa A, Mullins L, George D, Desbonnet C, Eidem TM, Montgomery JJ, Brown MF, Reilly U, Miller AA, O'Donnell JP. 2014. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. *mBio* 5:e01551-14. <http://dx.doi.org/10.1128/mBio.01551-14>.
85. McAllister LA, Montgomery JJ, Abramite JA, Reilly U, Brown MF, Chen JM, Barham RA, Che Y, Chung SW, Menard CA, Mitton-Fry M, Mullins LM, Noe MC, O'Donnell JP, Oliver RM, Penzien JB, Plummer M, Price LM, Shanmugasundaram V, Tomaras AP, Uccello DP. 2012. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. *Bioorg Med Chem Lett* 22:6832–6838. <http://dx.doi.org/10.1016/j.bmcl.2012.09.058>.

86. Kline T, Andersen NH, Harwood EA, Bowman J, Malanda A, Endsley S, Erwin AL, Doyle M, Fong S, Harris AL, Mendelsohn B, Mdluli K, Raetz CR, Stover CK, Witte PR, Yabannavar A, Zhu SG. 2002. Potent, novel in vitro inhibitors of the *Pseudomonas aeruginosa* deacetylase LpxC. *J Med Chem* 45:3112–3129. <http://dx.doi.org/10.1021/jm010579r>.
87. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmman DE. 2014. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against Gram-negative bacteria and in vivo efficacy. *Antimicrob Agents Chemother* 58:2657–2664. <http://dx.doi.org/10.1128/AAC.02778-13>.
88. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen D, Lagrutta A, Bradley P, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Wei CQ, Fukuda H, Kishii R, Takei M, Fukuda Y. 2014. Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. *ACS Med Chem Lett* 5:609–614. <http://dx.doi.org/10.1021/ml500069w>.
89. Tari LW, Li XM, Trzoss M, Bensen DC, Chen ZY, Lam T, Zhang JH, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J. 2013. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. *PLoS One* 8:e84409. <http://dx.doi.org/10.1371/journal.pone.0084409>.
90. Flamm RK, Rhomberg PR, Jones RN, Farrell DJ. 2015. In vitro activity of RX-P873 against Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 59:2280–2285. <http://dx.doi.org/10.1128/AAC.04840-14>.
91. Angus BL, Carey AM, Caron DA, Kropinski AM, Hancock RE. 1982. Outer membrane permeability in *Pseudomonas aeruginosa*—comparison of a wild-type with an antibiotic-supersusceptible mutant. *Antimicrob Agents Chemother* 21:299–309. <http://dx.doi.org/10.1128/AAC.21.2.299>.
92. Zimmermann W. 1979. Penetration through the Gram-negative cell wall: a co-determinant of the efficacy of beta-lactam antibiotics. *Int J Clin Pharmacol Biopharm* 17:131–134.
93. Balibar CJ, Iwanowicz D, Dean CR. 2013. Elongation factor P is dispensable in *Escherichia coli* and *Pseudomonas aeruginosa*. *Curr Microbiol* 67:293–299. <http://dx.doi.org/10.1007/s00284-013-0363-0>.
94. Shen X, Johnson NV, Jones AK, Barnes SW, Walker JR, Ranjitkar S, Woods AL, Six DA, Dean CR. 2014. Genetic characterization of the hypersusceptible *Pseudomonas aeruginosa* strain Z61: identification of a defect in LptE, abstr C-105. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
95. Angus BL, Fyfe JA, Hancock RE. 1987. Mapping and characterization of two mutations to antibiotic supersusceptibility in *Pseudomonas aeruginosa*. *J Gen Microbiol* 133:2905–2914.
96. Okamoto K, Gotoh N, Nishino T. 2001. *Pseudomonas aeruginosa* reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. *Antimicrob Agents Chemother* 45:1964–1971. <http://dx.doi.org/10.1128/AAC.45.7.1964-1971.2001>.
97. Gu YH, Stansfeld PJ, Zeng Y, Dong HH, Wang WJ, Dong CJ. 2015. Lipopolysaccharide is inserted into the outer membrane through an intramembrane hole, a lumen gate, and the lateral opening of LptD. *Structure* 23:496–504. <http://dx.doi.org/10.1016/j.str.2015.01.001>.
98. Qiao S, Luo QS, Zhao Y, Zhang XC, Huang Y. 2014. Structural basis for lipopolysaccharide insertion in the bacterial outer membrane. *Nature* 511:108–111. <http://dx.doi.org/10.1038/nature13484>.
99. Ruiz N, Wu T, Kahne D, Silhavy TJ. 2006. Probing the barrier function of the outer membrane with chemical conditionality. *ACS Chem Biol* 1:385–395. <http://dx.doi.org/10.1021/cb600128v>.
100. Eggert US, Ruiz N, Falcone BV, Branstrom AA, Goldman RC, Silhavy TJ, Kahne D. 2001. Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin. *Science* 294:361–364. <http://dx.doi.org/10.1126/science.1063611>.
101. Ruiz N, Falcone B, Kahne D, Silhavy TJ. 2005. Chemical conditionality: a genetic strategy to probe organelle assembly. *Cell* 121:307–317. <http://dx.doi.org/10.1016/j.cell.2005.02.014>.
102. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Kach A, Eberl L, Riedel K, DeMarco SJ, Robinson JA. 2010. Peptidomimetic antibiotics target outer-membrane biogenesis in *Pseudomonas aeruginosa*. *Science* 327:1010–1013. <http://dx.doi.org/10.1126/science.1182749>.
103. Werneburg M, Zerbe K, Juhas M, Bigler L, Stalder U, Kaech A, Ziegler U, Obrecht D, Eberl L, Robinson JA. 2012. Inhibition of lipopolysaccharide transport to the outer membrane in *Pseudomonas aeruginosa* by peptidomimetic antibiotics. *Chembiochem* 13:1767–1775. <http://dx.doi.org/10.1002/cbic.201200276>.